Pediatric Endocrinology and Metabolic Bone Diseases, Children's Hospital, Helsinki University Central Hospital and University of Helsinki, P.O. Box 281, FIN-00029 HUS, Helsinki, Finland.
J Clin Endocrinol Metab. 2012 Nov;97(11):4139-47. doi: 10.1210/jc.2012-1575. Epub 2012 Aug 29.
Guidelines in Finland recommend 10 μg of vitamin D3 daily for all infants. Recent observations suggest that this may be insufficient to maintain optimal serum 25-hydroxyvitamin D (S-25-OHD).
The aim of the study was to evaluate effects of various vitamin D doses and determine a dose ensuring S-25-OHD of at least 80 nmol/liter in infants without signs of vitamin D excess.
We conducted a randomized double-blind intervention study. Cord blood was obtained at birth for S-25-OHD; 113 infants were randomized to receive vitamin D3 10, 30, or 40 μg/d from age 2 wk to 3 months.
An investigator-initiated study was performed in a single maternity hospital in Helsinki, Finland.
S-25-OHD, calcium homeostasis, and skeletal characteristics were evaluated with peripheral quantitative computed tomography at age 3 months.
Baseline S-25-OHD was similar in all three groups (median, 53 nmol/liter). At 3 months, the mean S-25-OHD values were 88, 124, and 153 nmol/liter, and the minimum values were 46, 57, and 86 nmol/liter in the groups receiving 10, 30, and 40 μg (ANOVA; P < 0.001). No hypercalcemia occurred; plasma calcium, serum PTH, and urine calcium excretion was similar between the groups. Peripheral quantitative computed tomography showed a trend toward larger tibial total bone and cortical bone area with higher vitamin D doses.
Vitamin D3 supplementation with up to 40 μg/d from age 2 wk to 3 months was safe and caused no hypercalcemia or hypercalciuria. The 40-μg dose maintained S-25-OHD above 80 nmol/liter in all infants. More extensive and longer intervention studies are necessary to assess long-term effects.
芬兰的指南建议所有婴儿每天摄入 10 μg 的维生素 D3。最近的观察结果表明,这可能不足以维持最佳血清 25-羟维生素 D(S-25-OHD)水平。
本研究旨在评估不同维生素 D 剂量的效果,并确定一种剂量,以确保无维生素 D 过量迹象的婴儿的 S-25-OHD 至少达到 80 nmol/L。
我们进行了一项随机双盲干预研究。在出生时采集脐血进行 S-25-OHD 检测;113 名婴儿在 2 周龄至 3 个月龄时随机接受维生素 D3 10、30 或 40 μg/d。
这项由研究者发起的研究在芬兰赫尔辛基的一家妇产医院进行。
在 3 个月龄时,使用外周定量计算机断层扫描评估 S-25-OHD、钙稳态和骨骼特征。
三组的基线 S-25-OHD 相似(中位数为 53 nmol/L)。在 3 个月时,平均 S-25-OHD 值分别为 88、124 和 153 nmol/L,最低值分别为 46、57 和 86 nmol/L,分别接受 10、30 和 40 μg 的组(方差分析;P<0.001)。未发生高钙血症;各组的血浆钙、血清甲状旁腺激素和尿钙排泄均相似。外周定量计算机断层扫描显示,随着维生素 D 剂量的增加,胫骨总骨和皮质骨面积有增大的趋势。
从 2 周龄至 3 个月龄,每天补充高达 40 μg 的维生素 D3 是安全的,不会导致高钙血症或高钙尿症。40 μg 剂量可使所有婴儿的 S-25-OHD 保持在 80 nmol/L 以上。需要进行更广泛和更长时间的干预研究,以评估长期效果。